Despite analysts downgrading revenue estimates and increasing loss per share forecasts for Akeso, the consensus price target remains steady. However, Akeso's revenues are expected to underperform the wider industry.
Akeso's weaker revenue outlook doesn't impact its P/S ratio as much as expected, posing a risk to investors. The share price may fall if low revenue growth affects sentiment. Investors should consider this risk before investing.
$Hang Seng Index(800000.HK)$plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion. Pharmaceuticals were sold off.$REMEGEN-B(09995.HK)$once collapsed 27.5% to $22.8; last at $24.9, down 21%. $CLOVER BIO-B(02197.HK)$nosedived 9.6% to $0.47, hitting record low.$維亜生物科技(01873.HK)$...
Akeso's low P/S ratio indicates shareholder discomfort over its weak future revenue forecast. The market's gloomy sentiment about the company's growth prospects affects the low P/S ratio.
Akeso's strong net cash position and high liquidity suggest a low risk in its debt usage. The large conversion rate of EBIT to free cash flow also signals a positive financial health and potential profitability.
Key points: 1. Hang Seng Index fell 2.57% in the first two weeks (2023/05/22 to 2023/06/02), with all 12 Hang Seng industries falling. Among them, the Hang Seng healthcare sector fell 1.51%, outperforming the Hang Seng Index by 1.06 percentage points, ranking third among the 12 Hang Seng industries 2. On May 22, the results of the f...
$康方生物科技(09926.HK)$Excellent clinical data, focus on product launch and data disclosure Phase II clinical trial of AK112 combined with paclitaxel and chemotherapy in advanced non-small cell lung cancer Objective sustained release rate (ORR) 53.8%, disease control rate (DCR) 100%, grade 3 or above treatment The incidence of related adverse events was 13.5%. In combination with the PARP inhibitor olaparil for ovarian cancer Phase Ib/II clinical, ORR/DCR 40.0%/86.7%. We expect it to be around 2024 on the market.
康方生物科技に関するコメント
HSI Plunge Once Deepens to 620 Pts; Pharmas In Sell-off
Pharmaceuticals were sold off. $REMEGEN-B(09995.HK)$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B(02197.HK)$ nosedived 9.6% to $0.47, hitting record low. $維亜生物科技(01873.HK)$ ...
コラムAnxin International - Pharmaceutical Industry Biweekly Report: The results of Chinese medicine decoction pieces combined selection landing, 2023ASCO abstract released
1. Hang Seng Index fell 2.57% in the first two weeks (2023/05/22 to 2023/06/02), with all 12 Hang Seng industries falling. Among them, the Hang Seng healthcare sector fell 1.51%, outperforming the Hang Seng Index by 1.06 percentage points, ranking third among the 12 Hang Seng industries
2. On May 22, the results of the f...
Phase II clinical trial of AK112 combined with paclitaxel and chemotherapy in advanced non-small cell lung cancer
Objective sustained release rate (ORR) 53.8%, disease control rate (DCR) 100%, grade 3 or above treatment
The incidence of related adverse events was 13.5%. In combination with the PARP inhibitor olaparil for ovarian cancer
Phase Ib/II clinical, ORR/DCR 40.0%/86.7%. We expect it to be around 2024 on the market.
まだコメントはありません